[
  {
    "bcr_patient_uuid": "f9204a59-6877-4d06-a20e-fd7ab0859ed5",
    "patient_ID": "TCGA.AF.2687",
    "bcr_drug_barcode": "TCGA-AF-2687-D7471",
    "bcr_drug_uuid": "3041c9c2-446a-4fd8-a6b7-b4ea72dda4fd",
    "form_completion_date": "2011-2-9",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 97,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 1500,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "f9204a59-6877-4d06-a20e-fd7ab0859ed5",
    "patient_ID": "TCGA.AF.2687",
    "bcr_drug_barcode": "TCGA-AF-2687-D7476",
    "bcr_drug_uuid": "0d0a7050-6694-40d7-8087-f5ea54967092",
    "form_completion_date": "2011-2-9",
    "pharmaceutical_therapy_drug_name": "5 FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 261,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 34193
  },
  {
    "bcr_patient_uuid": "f9204a59-6877-4d06-a20e-fd7ab0859ed5",
    "patient_ID": "TCGA.AF.2687",
    "bcr_drug_barcode": "TCGA-AF-2687-D7474",
    "bcr_drug_uuid": "b1351850-ce3f-4280-8c28-f967e6a594a3",
    "form_completion_date": "2011-2-9",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 259,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 5750
  },
  {
    "bcr_patient_uuid": "f9204a59-6877-4d06-a20e-fd7ab0859ed5",
    "patient_ID": "TCGA.AF.2687",
    "bcr_drug_barcode": "TCGA-AF-2687-D7473",
    "bcr_drug_uuid": "66493de1-960a-4d78-abdb-ad820db8bfc4",
    "form_completion_date": "2011-2-9",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 259,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1211
  },
  {
    "bcr_patient_uuid": "f9204a59-6877-4d06-a20e-fd7ab0859ed5",
    "patient_ID": "TCGA.AF.2687",
    "bcr_drug_barcode": "TCGA-AF-2687-D7475",
    "bcr_drug_uuid": "e024567d-988f-4c5f-b624-b18ee2d0bc40",
    "form_completion_date": "2011-2-9",
    "pharmaceutical_therapy_drug_name": "5 FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 259,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 5699
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3030",
    "bcr_drug_uuid": "22e444fa-7135-4389-bad0-7f7bcdc45420",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY|OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 316,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 346,
    "drug_cycles": 3,
    "pharma_type_other": "VELOUR 10262 STUDY- AFLIBERCEPT/PLACEBO (4MG/KG) EVERY 2 WEEKS WITH IRINOTECAN/5FU COMBINATION (FOLFIRI)",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 10296
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D2998",
    "bcr_drug_uuid": "0cd90c9e-bd4f-4cbf-ad1d-dd6d457912e7",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 267,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 7032
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D2996",
    "bcr_drug_uuid": "772bc81b-8c06-48f0-a915-68df8ceba7eb",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 267,
    "drug_cycles": 12,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 600,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 7200
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3001",
    "bcr_drug_uuid": "6dd36a05-450e-45a0-b0c5-579a3b63651b",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 42192
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3024",
    "bcr_drug_uuid": "e843e98b-59be-4d00-b606-7eaf5e9d9ac7",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY|OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 316,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 344,
    "drug_cycles": 3,
    "pharma_type_other": "VELOUR 10262 STUDY- AFLIBERCEPT/PLACEBO (4MG/KG) EVERY 2 WEEKS WITH IRINOTECAN/5FU COMBINATION (FOLFIRI)",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 772
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3028",
    "bcr_drug_uuid": "4d891da7-ccc2-4b3e-b531-0bbd6385e6a6",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 316,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 344,
    "drug_cycles": 3,
    "pharma_type_other": "OTHER ANCILLARY-VELOUR 10262 STUDY- AFLIBERCEPT/PLACEBO (4MG/KG) EVERY 2 WEEKS WITH IRINOTECAN/5FU COMBINATION (FOLFIRI)",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 1716
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D2997",
    "bcr_drug_uuid": "8675aae4-8055-487a-b80a-4e53c4629f87",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 267,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 707
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3029",
    "bcr_drug_uuid": "1dcab074-5ee4-4818-89bf-d7fdd9de8818",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY|OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 316,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 344,
    "drug_cycles": 3,
    "pharma_type_other": "VELOUR 10262 STUDY- AFLIBERCEPT/PLACEBO (4MG/KG) EVERY 2 WEEKS WITH IRINOTECAN/5FU COMBINATION (FOLFIRI)",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 1716
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D2991",
    "bcr_drug_uuid": "5ae8e910-5b3a-4fb0-8bd2-f37b9756c396",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 85,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "drug_cycles": 10,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 2363.5
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3007",
    "bcr_drug_uuid": "bf52814b-2808-468b-9ae6-49608c492c80",
    "form_completion_date": "2010-11-5",
    "pharmaceutical_therapy_drug_name": "AFLIBERCEPT/ PLACEBO STUDY",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 316,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 344,
    "drug_cycles": 3,
    "pharma_type_other": "VELOUR 10262 STUDY- AFLIBERCEPT/PLACEBO (4MG/KG) EVERY 2 WEEKS WITH IRINOTECAN/5FU COMBINATION (FOLFIRI)",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION",
    "drug_total_dose": 537
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3309",
    "bcr_drug_uuid": "7eefebc0-11fd-4028-87c6-cab921f47ab3",
    "form_completion_date": "2010-11-12",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 462,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3307",
    "bcr_drug_uuid": "5df65b50-c401-4ff5-af88-293a113e284a",
    "form_completion_date": "2010-11-12",
    "pharmaceutical_therapy_drug_name": "FUDR (FLOXURIDINE)",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 379,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D3308",
    "bcr_drug_uuid": "8c673e37-976e-454d-841d-a0888f2d93ed",
    "form_completion_date": "2010-11-12",
    "pharmaceutical_therapy_drug_name": "CAMPTOSAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 379,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "335d0351-3740-4847-9ff4-be2f078c70f7",
    "patient_ID": "TCGA.AF.2689",
    "bcr_drug_barcode": "TCGA-AF-2689-D4053",
    "bcr_drug_uuid": "62a137f0-ba1f-4bfa-a6cc-cfe749a79ca4",
    "form_completion_date": "2010-11-24",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 379,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 559,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "71a32fca-d48f-4ea3-8df7-69f9dda8fa91",
    "patient_ID": "TCGA.AF.2692",
    "bcr_drug_barcode": "TCGA-AF-2692-D9921",
    "bcr_drug_uuid": "8d16b3a4-228c-430e-a26c-6747b843381d",
    "form_completion_date": "2010-12-21",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 344,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 384,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 1500,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE",
    "drug_total_dose": 87000
  },
  {
    "bcr_patient_uuid": "cbcb2141-b415-4410-8dd7-2a3cd3980a19",
    "patient_ID": "TCGA.AF.3400",
    "bcr_drug_barcode": "TCGA-AF-3400-D2753",
    "bcr_drug_uuid": "3ec1df07-49b6-45d9-abb2-137d5d95525f",
    "form_completion_date": "2010-11-3",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 97,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 14005
  },
  {
    "bcr_patient_uuid": "cbcb2141-b415-4410-8dd7-2a3cd3980a19",
    "patient_ID": "TCGA.AF.3400",
    "bcr_drug_barcode": "TCGA-AF-3400-D2800",
    "bcr_drug_uuid": "0e287f64-1843-4bfa-a0e8-19be31c3cb81",
    "form_completion_date": "2010-11-4",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 185,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 358,
    "drug_cycles": 11,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 6850
  },
  {
    "bcr_patient_uuid": "cbcb2141-b415-4410-8dd7-2a3cd3980a19",
    "patient_ID": "TCGA.AF.3400",
    "bcr_drug_barcode": "TCGA-AF-3400-D2850",
    "bcr_drug_uuid": "a2e12b5b-e00e-4614-aaa9-973b603d189c",
    "form_completion_date": "2010-11-4",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 185,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 360,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 44067
  },
  {
    "bcr_patient_uuid": "cbcb2141-b415-4410-8dd7-2a3cd3980a19",
    "patient_ID": "TCGA.AF.3400",
    "bcr_drug_barcode": "TCGA-AF-3400-D2833",
    "bcr_drug_uuid": "f5420dc8-d394-4f7f-9848-008df8cbc84b",
    "form_completion_date": "2010-11-4",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 185,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 358,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1551
  },
  {
    "bcr_patient_uuid": "cbcb2141-b415-4410-8dd7-2a3cd3980a19",
    "patient_ID": "TCGA.AF.3400",
    "bcr_drug_barcode": "TCGA-AF-3400-D2847",
    "bcr_drug_uuid": "2a24fcad-f207-47b7-87cf-f710d38df559",
    "form_completion_date": "2010-11-4",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 185,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 358,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 7300
  },
  {
    "bcr_patient_uuid": "17e286b7-7793-446d-b556-1108addb5ba2",
    "patient_ID": "TCGA.AF.3911",
    "bcr_drug_barcode": "TCGA-AF-3911-D13478",
    "bcr_drug_uuid": "9cf10576-9771-4a03-ab78-4c2dc302073e",
    "form_completion_date": "2011-6-28",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 145,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 285,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1868
  },
  {
    "bcr_patient_uuid": "17e286b7-7793-446d-b556-1108addb5ba2",
    "patient_ID": "TCGA.AF.3911",
    "bcr_drug_barcode": "TCGA-AF-3911-D13479",
    "bcr_drug_uuid": "378a1cdd-b199-4005-b5a8-590fe60c777c",
    "form_completion_date": "2011-6-28",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 145,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 300,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 10296
  },
  {
    "bcr_patient_uuid": "17e286b7-7793-446d-b556-1108addb5ba2",
    "patient_ID": "TCGA.AF.3911",
    "bcr_drug_barcode": "TCGA-AF-3911-D13480",
    "bcr_drug_uuid": "763988bf-65bc-4af6-affa-2d62417e581e",
    "form_completion_date": "2011-6-28",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 145,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 300,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 6200
  },
  {
    "bcr_patient_uuid": "17e286b7-7793-446d-b556-1108addb5ba2",
    "patient_ID": "TCGA.AF.3911",
    "bcr_drug_barcode": "TCGA-AF-3911-D13481",
    "bcr_drug_uuid": "ac0aeb25-48f3-4491-a888-09bc7cd2757f",
    "form_completion_date": "2011-6-28",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 145,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 302,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 61776
  },
  {
    "bcr_patient_uuid": "17e286b7-7793-446d-b556-1108addb5ba2",
    "patient_ID": "TCGA.AF.3911",
    "bcr_drug_barcode": "TCGA-AF-3911-D13456",
    "bcr_drug_uuid": "93f15563-e1f4-4df9-98fe-2c058fa1aef0",
    "form_completion_date": "2011-7-18",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 106,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 13271
  },
  {
    "bcr_patient_uuid": "03a9dd9d-62ae-4acd-9272-389274858f3d",
    "patient_ID": "TCGA.AF.3913",
    "bcr_drug_barcode": "TCGA-AF-3913-D15342",
    "bcr_drug_uuid": "37cd71bc-2e4e-467d-8695-ebb6dae9c2e0",
    "form_completion_date": "2011-9-19",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 231,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 313,
    "drug_cycles": 3,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "PALLIATIVE"
  },
  {
    "bcr_patient_uuid": "03a9dd9d-62ae-4acd-9272-389274858f3d",
    "patient_ID": "TCGA.AF.3913",
    "bcr_drug_barcode": "TCGA-AF-3913-D15339",
    "bcr_drug_uuid": "55dec849-87fa-4e9d-b34a-25d3f86fd865",
    "form_completion_date": "2011-9-19",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 231,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 313,
    "drug_cycles": 3,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE"
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D10865",
    "bcr_drug_uuid": "742fb3eb-c8eb-4377-ad4b-8f106d302e97",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 294,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1643
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D10887",
    "bcr_drug_uuid": "70ef1e70-9652-476a-a268-1280652bb1a8",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "5 FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 294,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 7918
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D10888",
    "bcr_drug_uuid": "9f639bf0-67cc-4ca3-a738-c7f03a214b21",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "5 FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 296,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D10886",
    "bcr_drug_uuid": "caf0a7a9-d006-46fa-9810-3cb754a26c74",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 294,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 3150
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D10864",
    "bcr_drug_uuid": "359d8f95-b037-463b-bebb-679c31c0ef3e",
    "form_completion_date": "2011-4-28",
    "pharmaceutical_therapy_drug_name": "5 FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 105,
    "drug_cycles": 7,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 12265
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D41485",
    "bcr_drug_uuid": "AC84D228-12BE-44DA-A004-F09C1B574F03",
    "form_completion_date": "2013-3-19",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 924,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1134,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D41486",
    "bcr_drug_uuid": "9BF0B463-F451-4BB4-BB19-1675656AE60F",
    "form_completion_date": "2013-3-19",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 924,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1022,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D41487",
    "bcr_drug_uuid": "DB0F22AA-0122-4C85-9E00-07A45715A0B0",
    "form_completion_date": "2013-3-19",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 924,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1022,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D41488",
    "bcr_drug_uuid": "E946FC49-AEB3-4A51-B943-CDA7CC4A7A31",
    "form_completion_date": "2013-3-19",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 924,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1022,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3f2ca278-c74a-4aa7-b029-189d9d0b510c",
    "patient_ID": "TCGA.AF.3914",
    "bcr_drug_barcode": "TCGA-AF-3914-D41489",
    "bcr_drug_uuid": "A35156FA-AFFB-498C-AE11-E35ECC46908E",
    "form_completion_date": "2013-3-19",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL IV CONTINUOUS INFUSION OVER 46 HOURS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 924,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1024,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5f10f8e4-a6f9-4643-b210-390bc8fd32bd",
    "patient_ID": "TCGA.AF.4110",
    "bcr_drug_barcode": "TCGA-AF-4110-D13664",
    "bcr_drug_uuid": "0916a9a1-c34b-4f5f-82d9-bd1d903c605e",
    "form_completion_date": "2011-7-7",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 261,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 875,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 7875
  },
  {
    "bcr_patient_uuid": "5f10f8e4-a6f9-4643-b210-390bc8fd32bd",
    "patient_ID": "TCGA.AF.4110",
    "bcr_drug_barcode": "TCGA-AF-4110-D13665",
    "bcr_drug_uuid": "ea9270b1-82ca-4900-a127-946f0ec99902",
    "form_completion_date": "2011-7-7",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 261,
    "drug_cycles": 9,
    "pharma_type_other": "LEUCOVORIN",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 5875
  },
  {
    "bcr_patient_uuid": "5f10f8e4-a6f9-4643-b210-390bc8fd32bd",
    "patient_ID": "TCGA.AF.4110",
    "bcr_drug_barcode": "TCGA-AF-4110-D13666",
    "bcr_drug_uuid": "cbc1140c-d519-4b62-90fa-5fe35623fa70",
    "form_completion_date": "2011-7-7",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 263,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 5200,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 46800
  },
  {
    "bcr_patient_uuid": "5f10f8e4-a6f9-4643-b210-390bc8fd32bd",
    "patient_ID": "TCGA.AF.4110",
    "bcr_drug_barcode": "TCGA-AF-4110-D13658",
    "bcr_drug_uuid": "8e82086a-6e5b-4fd9-b884-c08049426228",
    "form_completion_date": "2011-7-7",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 261,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 185,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1665
  },
  {
    "bcr_patient_uuid": "5bc1db25-3e25-44d7-99cb-e31f00cf1d58",
    "patient_ID": "TCGA.AF.6136",
    "bcr_drug_barcode": "TCGA-AF-6136-D31526",
    "bcr_drug_uuid": "6a8a2d9a-dceb-4ed9-8bfc-76a4c6c10c28",
    "form_completion_date": "2012-5-9",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 209,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 385,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5bc1db25-3e25-44d7-99cb-e31f00cf1d58",
    "patient_ID": "TCGA.AF.6136",
    "bcr_drug_barcode": "TCGA-AF-6136-D31527",
    "bcr_drug_uuid": "54ada04a-3ac3-487d-b98b-814256e83be5",
    "form_completion_date": "2012-5-9",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 209,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 454,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5bc1db25-3e25-44d7-99cb-e31f00cf1d58",
    "patient_ID": "TCGA.AF.6136",
    "bcr_drug_barcode": "TCGA-AF-6136-D31528",
    "bcr_drug_uuid": "1419103a-d51d-4461-bb13-1a18acce6ed3",
    "form_completion_date": "2012-5-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 209,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 454,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5bc1db25-3e25-44d7-99cb-e31f00cf1d58",
    "patient_ID": "TCGA.AF.6136",
    "bcr_drug_barcode": "TCGA-AF-6136-D31529",
    "bcr_drug_uuid": "b031c881-0b3e-4778-bc63-28d0e2bf4c48",
    "form_completion_date": "2012-5-9",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 209,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 453,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5bc1db25-3e25-44d7-99cb-e31f00cf1d58",
    "patient_ID": "TCGA.AF.6136",
    "bcr_drug_barcode": "TCGA-AF-6136-D31525",
    "bcr_drug_uuid": "e005c38c-40ff-4493-815b-770c79d550ad",
    "form_completion_date": "2012-5-11",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 117,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6221496d-40cc-4071-969f-6fbcba4f573c",
    "patient_ID": "TCGA.AF.6672",
    "bcr_drug_barcode": "TCGA-AF-6672-D19807",
    "bcr_drug_uuid": "dac0f8bc-2057-4165-bc75-9907572612fc",
    "form_completion_date": "2011-12-27",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 199,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 51786
  },
  {
    "bcr_patient_uuid": "6221496d-40cc-4071-969f-6fbcba4f573c",
    "patient_ID": "TCGA.AF.6672",
    "bcr_drug_barcode": "TCGA-AF-6672-D19804",
    "bcr_drug_uuid": "3bf645a0-d4bb-4afe-85e0-bfbe69b64c7e",
    "form_completion_date": "2011-12-27",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 183,
    "drug_cycles": 11,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1578
  },
  {
    "bcr_patient_uuid": "6221496d-40cc-4071-969f-6fbcba4f573c",
    "patient_ID": "TCGA.AF.6672",
    "bcr_drug_barcode": "TCGA-AF-6672-D19805",
    "bcr_drug_uuid": "6ff436f2-b6b7-4a69-a1aa-cbc6fe45a89f",
    "form_completion_date": "2011-12-27",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "drug_cycles": 12,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1400
  },
  {
    "bcr_patient_uuid": "6221496d-40cc-4071-969f-6fbcba4f573c",
    "patient_ID": "TCGA.AF.6672",
    "bcr_drug_barcode": "TCGA-AF-6672-D19806",
    "bcr_drug_uuid": "5d946f3e-2226-4819-bca2-6f6831cae629",
    "form_completion_date": "2011-12-27",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 43,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 197,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 8639
  },
  {
    "bcr_patient_uuid": "C8FD1040-82A2-4CDA-AC49-C2F82B20CBAB",
    "patient_ID": "TCGA.AF.A56L",
    "bcr_drug_barcode": "TCGA-AF-A56L-D42409",
    "bcr_drug_uuid": "B297C576-C11B-4810-B6C6-C2859AF3D1DE",
    "form_completion_date": "2013-4-18",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 255,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C8FD1040-82A2-4CDA-AC49-C2F82B20CBAB",
    "patient_ID": "TCGA.AF.A56L",
    "bcr_drug_barcode": "TCGA-AF-A56L-D42410",
    "bcr_drug_uuid": "C6E884C2-2F25-4791-8E07-CF6A9034F43D",
    "form_completion_date": "2013-4-18",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 255,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C8FD1040-82A2-4CDA-AC49-C2F82B20CBAB",
    "patient_ID": "TCGA.AF.A56L",
    "bcr_drug_barcode": "TCGA-AF-A56L-D42411",
    "bcr_drug_uuid": "B413308D-C7F5-4902-8FF1-D44C8696D792",
    "form_completion_date": "2013-4-18",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 255,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C8FD1040-82A2-4CDA-AC49-C2F82B20CBAB",
    "patient_ID": "TCGA.AF.A56L",
    "bcr_drug_barcode": "TCGA-AF-A56L-D42412",
    "bcr_drug_uuid": "7CF68531-04CC-4FC7-B1CA-17DB824739E0",
    "form_completion_date": "2013-4-18",
    "pharmaceutical_therapy_drug_name": "5FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 255,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "811F3FEB-A5A9-48B1-ACDA-FBB23FCBCF16",
    "patient_ID": "TCGA.AF.A56N",
    "bcr_drug_barcode": "TCGA-AF-A56N-D42111",
    "bcr_drug_uuid": "5A29766B-D0E7-47E8-BB9B-21A9A9E7F331",
    "form_completion_date": "2013-4-11",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 95,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "811F3FEB-A5A9-48B1-ACDA-FBB23FCBCF16",
    "patient_ID": "TCGA.AF.A56N",
    "bcr_drug_barcode": "TCGA-AF-A56N-D42114",
    "bcr_drug_uuid": "9BCDA4FD-AF03-4003-9FD6-36343C7BB81C",
    "form_completion_date": "2013-4-11",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 159,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 347,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37619",
    "bcr_drug_uuid": "FB261DCE-FD6C-4A15-AA2E-ABE3012E6B22",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 274,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37620",
    "bcr_drug_uuid": "079392F9-28CE-40D9-8097-908D753F5F41",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 274,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37621",
    "bcr_drug_uuid": "1B4F9FA3-8976-4771-B187-EAFB66D56DB9",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 274,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37622",
    "bcr_drug_uuid": "A2894A8C-69C0-42F7-8A2F-F63A9150C893",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 335,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 396,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37623",
    "bcr_drug_uuid": "6B518DAA-0328-44A6-902E-ED9122718F0D",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 335,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 396,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37624",
    "bcr_drug_uuid": "5C31B440-ED68-435C-89C1-337C2C1B9498",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 335,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 396,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37625",
    "bcr_drug_uuid": "C91698E7-82FD-4FD9-B3C7-50E589A064F5",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 427,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 580,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37626",
    "bcr_drug_uuid": "7F381F5C-41AD-4C61-974F-48B497AA77D4",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 427,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 580,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b2c48624-a483-4b1d-9155-c0c80ed2f7a0",
    "patient_ID": "TCGA.AG.3584",
    "bcr_drug_barcode": "TCGA-AG-3584-D37627",
    "bcr_drug_uuid": "B834783E-DAAC-45FF-9BDC-028EB4A7A879",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 427,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 580,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a2b6246d-2b80-49c5-968b-694b4e8171dc",
    "patient_ID": "TCGA.AG.3591",
    "bcr_drug_barcode": "TCGA-AG-3591-D37628",
    "bcr_drug_uuid": "08A34556-1CC3-4842-91F9-25E1D7455F1E",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "10290e91-9784-4f94-8daa-b5d9a8b0efb9",
    "patient_ID": "TCGA.AG.3593",
    "bcr_drug_barcode": "TCGA-AG-3593-D37629",
    "bcr_drug_uuid": "F0328A7A-9B62-404F-AC16-CA9495F2E404",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17a8d208-fcf6-4480-945c-848d4234aafd",
    "patient_ID": "TCGA.AG.3600",
    "bcr_drug_barcode": "TCGA-AG-3600-D37630",
    "bcr_drug_uuid": "69707452-630C-4BFE-A48F-B625078F02D9",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "81dac02c-6e5f-4afe-9c90-12b5a4f26594",
    "patient_ID": "TCGA.AG.3609",
    "bcr_drug_barcode": "TCGA-AG-3609-D37631",
    "bcr_drug_uuid": "DA3F2436-7363-4949-967D-5030F2F0C5D2",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "81dac02c-6e5f-4afe-9c90-12b5a4f26594",
    "patient_ID": "TCGA.AG.3609",
    "bcr_drug_barcode": "TCGA-AG-3609-D37632",
    "bcr_drug_uuid": "5E269C7F-6E92-4C6D-BC05-F089CC7FCA62",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "81dac02c-6e5f-4afe-9c90-12b5a4f26594",
    "patient_ID": "TCGA.AG.3609",
    "bcr_drug_barcode": "TCGA-AG-3609-D37633",
    "bcr_drug_uuid": "AE9AEFB7-BB2B-4B63-B031-2CAF2DB86DC3",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 90,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "fb632146-92c7-40d9-acc3-6dc4a2d499be",
    "patient_ID": "TCGA.AG.3611",
    "bcr_drug_barcode": "TCGA-AG-3611-D37634",
    "bcr_drug_uuid": "40EA7062-DFF9-4BC9-9EBA-7AF603EFA401",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 850,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 973,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "fb632146-92c7-40d9-acc3-6dc4a2d499be",
    "patient_ID": "TCGA.AG.3611",
    "bcr_drug_barcode": "TCGA-AG-3611-D37635",
    "bcr_drug_uuid": "0D72C3B9-12DB-45F9-8E9B-575140447392",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 850,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 973,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1543c1da-bde4-41c1-a510-56b62db8cca8",
    "patient_ID": "TCGA.AG.3612",
    "bcr_drug_barcode": "TCGA-AG-3612-D37636",
    "bcr_drug_uuid": "C4769825-6F3B-421E-B75C-5FEFBE760F7A",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 273,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1543c1da-bde4-41c1-a510-56b62db8cca8",
    "patient_ID": "TCGA.AG.3612",
    "bcr_drug_barcode": "TCGA-AG-3612-D37637",
    "bcr_drug_uuid": "ED6FBE6C-F021-4A62-8F36-809D25748C6B",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 273,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1543c1da-bde4-41c1-a510-56b62db8cca8",
    "patient_ID": "TCGA.AG.3612",
    "bcr_drug_barcode": "TCGA-AG-3612-D37638",
    "bcr_drug_uuid": "24C1B6B1-A537-45CC-AFFF-36F91F5F59D9",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 59,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "856a490c-c6da-48fe-88b5-9fde0f481365",
    "patient_ID": "TCGA.AG.3728",
    "bcr_drug_barcode": "TCGA-AG-3728-D37639",
    "bcr_drug_uuid": "53588706-BC6B-405C-A6D2-4C7953641320",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 61,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "856a490c-c6da-48fe-88b5-9fde0f481365",
    "patient_ID": "TCGA.AG.3728",
    "bcr_drug_barcode": "TCGA-AG-3728-D37640",
    "bcr_drug_uuid": "73B9ADC4-8BF1-4085-B885-844051A7F688",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 61,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "856a490c-c6da-48fe-88b5-9fde0f481365",
    "patient_ID": "TCGA.AG.3728",
    "bcr_drug_barcode": "TCGA-AG-3728-D37641",
    "bcr_drug_uuid": "294E64A4-AE56-42C8-A708-559C0DD9689A",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 61,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72756208-a5ed-47d2-8c4c-19a8d39f7b9d",
    "patient_ID": "TCGA.AG.3731",
    "bcr_drug_barcode": "TCGA-AG-3731-D37642",
    "bcr_drug_uuid": "89CD8582-B07D-4C29-ABEB-E59268AC7FD7",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 914,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72756208-a5ed-47d2-8c4c-19a8d39f7b9d",
    "patient_ID": "TCGA.AG.3731",
    "bcr_drug_barcode": "TCGA-AG-3731-D37643",
    "bcr_drug_uuid": "0050963E-70D9-4754-BD4D-5CB6943EDB8A",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 914,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72756208-a5ed-47d2-8c4c-19a8d39f7b9d",
    "patient_ID": "TCGA.AG.3731",
    "bcr_drug_barcode": "TCGA-AG-3731-D37644",
    "bcr_drug_uuid": "D24F50D6-FB52-4277-8AB4-AC5123C639C7",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 184,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72756208-a5ed-47d2-8c4c-19a8d39f7b9d",
    "patient_ID": "TCGA.AG.3731",
    "bcr_drug_barcode": "TCGA-AG-3731-D37645",
    "bcr_drug_uuid": "ABCED613-88E1-44F3-8477-B6B2A8C63CF9",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 365,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 914,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a83923fd-276c-4526-9922-5ef741f551fd",
    "patient_ID": "TCGA.AG.3732",
    "bcr_drug_barcode": "TCGA-AG-3732-D37646",
    "bcr_drug_uuid": "E3DA3054-7188-4C70-B09A-AAE3757CB1F5",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1277,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1673,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a83923fd-276c-4526-9922-5ef741f551fd",
    "patient_ID": "TCGA.AG.3732",
    "bcr_drug_barcode": "TCGA-AG-3732-D37647",
    "bcr_drug_uuid": "F553079B-0B3B-485C-A8D3-B2D83729DB97",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1277,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1673,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e5e4aa9f-6015-4d62-a088-69920d7f2500",
    "patient_ID": "TCGA.AG.3885",
    "bcr_drug_barcode": "TCGA-AG-3885-D37648",
    "bcr_drug_uuid": "C4BBC4E0-3D66-4633-A05D-4A68AE87C8A7",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "e5e4aa9f-6015-4d62-a088-69920d7f2500",
    "patient_ID": "TCGA.AG.3885",
    "bcr_drug_barcode": "TCGA-AG-3885-D37649",
    "bcr_drug_uuid": "78CE6B50-B0DA-403C-A9CF-FFF157A9C0CC",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "ZOLEDRONIC ACID",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 365,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8c7ccdb0-7653-4a8d-86b6-de39afc40765",
    "patient_ID": "TCGA.AG.3887",
    "bcr_drug_barcode": "TCGA-AG-3887-D37650",
    "bcr_drug_uuid": "B21661DA-72BC-41E0-8FB1-7FD3C9904564",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1095,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8c7ccdb0-7653-4a8d-86b6-de39afc40765",
    "patient_ID": "TCGA.AG.3887",
    "bcr_drug_barcode": "TCGA-AG-3887-D37651",
    "bcr_drug_uuid": "D19E88BF-FD23-407D-8687-8DBC9EF02F86",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1095,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8c7ccdb0-7653-4a8d-86b6-de39afc40765",
    "patient_ID": "TCGA.AG.3887",
    "bcr_drug_barcode": "TCGA-AG-3887-D37652",
    "bcr_drug_uuid": "8EDBD3BB-086B-4166-A971-A245C564BF9C",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1095,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "add567b7-29ef-4122-8a54-57d36f735e78",
    "patient_ID": "TCGA.AG.3893",
    "bcr_drug_barcode": "TCGA-AG-3893-D37653",
    "bcr_drug_uuid": "D8A5AC42-4F51-4626-BFAB-BF6CD4C44D3C",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 245,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "add567b7-29ef-4122-8a54-57d36f735e78",
    "patient_ID": "TCGA.AG.3893",
    "bcr_drug_barcode": "TCGA-AG-3893-D37654",
    "bcr_drug_uuid": "1680F252-BB88-454F-B1CC-FE1038F33269",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 245,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "065b26fc-6827-44d5-83d8-1100c63fcda6",
    "patient_ID": "TCGA.AG.3894",
    "bcr_drug_barcode": "TCGA-AG-3894-D37655",
    "bcr_drug_uuid": "E4102A2F-8A6F-4B7C-9E20-3970FC3DD124",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 245,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "769880ae-34d9-405e-8ea7-33ba47cf2dd2",
    "patient_ID": "TCGA.AG.3909",
    "bcr_drug_barcode": "TCGA-AG-3909-D37656",
    "bcr_drug_uuid": "9844876F-EB16-49BC-86DC-FCCAC4BD3B19",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 243,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "769880ae-34d9-405e-8ea7-33ba47cf2dd2",
    "patient_ID": "TCGA.AG.3909",
    "bcr_drug_barcode": "TCGA-AG-3909-D37657",
    "bcr_drug_uuid": "AAB0F90D-B954-464B-9589-2484E0399046",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 243,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "769880ae-34d9-405e-8ea7-33ba47cf2dd2",
    "patient_ID": "TCGA.AG.3909",
    "bcr_drug_barcode": "TCGA-AG-3909-D37658",
    "bcr_drug_uuid": "117DFF8F-E037-4B98-8108-AB8562BC27F8",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 182,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "60778da8-d99e-4e51-96a2-3e900b3978d9",
    "patient_ID": "TCGA.AG.3999",
    "bcr_drug_barcode": "TCGA-AG-3999-D37659",
    "bcr_drug_uuid": "4C69C48C-88A7-428F-85CB-0897E5F61623",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "866de12b-e4df-4f19-b62e-e3fd85d4ec08",
    "patient_ID": "TCGA.AG.4005",
    "bcr_drug_barcode": "TCGA-AG-4005-D37660",
    "bcr_drug_uuid": "217AFF88-4D43-42A3-9A3E-16D1662C2D28",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "866de12b-e4df-4f19-b62e-e3fd85d4ec08",
    "patient_ID": "TCGA.AG.4005",
    "bcr_drug_barcode": "TCGA-AG-4005-D37661",
    "bcr_drug_uuid": "DB8463A1-4C26-4AC4-9DEE-7392B21B8AA6",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "866de12b-e4df-4f19-b62e-e3fd85d4ec08",
    "patient_ID": "TCGA.AG.4005",
    "bcr_drug_barcode": "TCGA-AG-4005-D37662",
    "bcr_drug_uuid": "380000BA-B2B9-4D32-BA25-4E518DE0341C",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72802851-9340-4c5f-a90b-23b7afd7577a",
    "patient_ID": "TCGA.AG.4008",
    "bcr_drug_barcode": "TCGA-AG-4008-D37663",
    "bcr_drug_uuid": "5DD8AC7E-EEB1-4222-99A5-6B18A6A0B3CD",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72802851-9340-4c5f-a90b-23b7afd7577a",
    "patient_ID": "TCGA.AG.4008",
    "bcr_drug_barcode": "TCGA-AG-4008-D37664",
    "bcr_drug_uuid": "E2E9F3AE-4CA2-4A37-B87C-AD62DCF39099",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 92,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9084b672-8e65-4b7f-a256-32fd35aa8ab5",
    "patient_ID": "TCGA.AG.4022",
    "bcr_drug_barcode": "TCGA-AG-4022-D37665",
    "bcr_drug_uuid": "BA0BE627-3B95-403A-954D-635201C79CD6",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 153,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ff004403-8cc5-43e6-bd1c-dde4eb1e6193",
    "patient_ID": "TCGA.AG.A00C",
    "bcr_drug_barcode": "TCGA-AG-A00C-D37666",
    "bcr_drug_uuid": "0480C952-95AB-4119-B285-88C9B48B46CF",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ff004403-8cc5-43e6-bd1c-dde4eb1e6193",
    "patient_ID": "TCGA.AG.A00C",
    "bcr_drug_barcode": "TCGA-AG-A00C-D37667",
    "bcr_drug_uuid": "AB4C44C6-717B-46CA-8881-BCDB2B3C9D28",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ff004403-8cc5-43e6-bd1c-dde4eb1e6193",
    "patient_ID": "TCGA.AG.A00C",
    "bcr_drug_barcode": "TCGA-AG-A00C-D37668",
    "bcr_drug_uuid": "66F94F54-0A6F-4BA1-8050-01A385AB66F3",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 213,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9f4574ec-a58a-4410-8735-c5e5bc4ca7e0",
    "patient_ID": "TCGA.AG.A00H",
    "bcr_drug_barcode": "TCGA-AG-A00H-D37669",
    "bcr_drug_uuid": "F74BAE20-BD17-4DF8-9A05-AF806FEAA77A",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 90,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 121,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9c7b5e85-5579-4d0f-a7ea-b9d081ac0037",
    "patient_ID": "TCGA.AG.A016",
    "bcr_drug_barcode": "TCGA-AG-A016-D37670",
    "bcr_drug_uuid": "D17DDE62-D61E-4DC5-B0BD-069B51F864DC",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 245,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9c7b5e85-5579-4d0f-a7ea-b9d081ac0037",
    "patient_ID": "TCGA.AG.A016",
    "bcr_drug_barcode": "TCGA-AG-A016-D37671",
    "bcr_drug_uuid": "078B47FD-21FB-4FD2-8F32-E9DD57433938",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 61,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9c7b5e85-5579-4d0f-a7ea-b9d081ac0037",
    "patient_ID": "TCGA.AG.A016",
    "bcr_drug_barcode": "TCGA-AG-A016-D37672",
    "bcr_drug_uuid": "A029C8B8-87C1-462D-B804-E918A20290E6",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 245,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "848a5838-8a06-45a9-a3d6-e4ed47b824ab",
    "patient_ID": "TCGA.AG.A01L",
    "bcr_drug_barcode": "TCGA-AG-A01L-D37673",
    "bcr_drug_uuid": "8D57ECE2-11F5-4F08-8457-0FE7CAE7E643",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1118490d-75aa-43cc-b2a2-c2af61829ffc",
    "patient_ID": "TCGA.AG.A01N",
    "bcr_drug_barcode": "TCGA-AG-A01N-D37674",
    "bcr_drug_uuid": "8793E6F8-2AE4-419F-82DA-05F1528C6AF6",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 273,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1118490d-75aa-43cc-b2a2-c2af61829ffc",
    "patient_ID": "TCGA.AG.A01N",
    "bcr_drug_barcode": "TCGA-AG-A01N-D37675",
    "bcr_drug_uuid": "E059357B-5A89-48CC-B169-E79CDB764464",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 273,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 457,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1118490d-75aa-43cc-b2a2-c2af61829ffc",
    "patient_ID": "TCGA.AG.A01N",
    "bcr_drug_barcode": "TCGA-AG-A01N-D37676",
    "bcr_drug_uuid": "227136E0-CD9A-4B79-9777-3212A6324483",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 273,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "74543fa4-ce73-46e4-9c59-224e8242b4a2",
    "patient_ID": "TCGA.AG.A01W",
    "bcr_drug_barcode": "TCGA-AG-A01W-D37677",
    "bcr_drug_uuid": "E11038FD-3C7C-46DA-A03B-2AB5352DCDD5",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 184,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a91f7a8c-e0fe-403a-9ef0-f7679b2761cc",
    "patient_ID": "TCGA.AG.A01Y",
    "bcr_drug_barcode": "TCGA-AG-A01Y-D37678",
    "bcr_drug_uuid": "F99733D4-0119-416D-BCC9-791AD546EB61",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 151,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "19e46a3d-18c5-4927-8501-2265e2d617b8",
    "patient_ID": "TCGA.AG.A020",
    "bcr_drug_barcode": "TCGA-AG-A020-D37679",
    "bcr_drug_uuid": "AD098A28-2DA7-4BED-A331-5AA7358A8D28",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "19e46a3d-18c5-4927-8501-2265e2d617b8",
    "patient_ID": "TCGA.AG.A020",
    "bcr_drug_barcode": "TCGA-AG-A020-D37680",
    "bcr_drug_uuid": "3881A04C-1D82-4DD6-B894-53A283C12CBE",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "19e46a3d-18c5-4927-8501-2265e2d617b8",
    "patient_ID": "TCGA.AG.A020",
    "bcr_drug_barcode": "TCGA-AG-A020-D37681",
    "bcr_drug_uuid": "D2ADA08C-069D-430C-9642-E1F7DCC0513E",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 31,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17878cb0-a8f9-43a4-911c-0f94c2a5e3df",
    "patient_ID": "TCGA.AG.A02G",
    "bcr_drug_barcode": "TCGA-AG-A02G-D37682",
    "bcr_drug_uuid": "7458F01A-6F47-42AC-AB9F-525BFC8D3A2F",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": true,
    "days_to_drug_end": 1096,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17878cb0-a8f9-43a4-911c-0f94c2a5e3df",
    "patient_ID": "TCGA.AG.A02G",
    "bcr_drug_barcode": "TCGA-AG-A02G-D37683",
    "bcr_drug_uuid": "A6893A84-4202-474B-9A3D-78E7E865113C",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1096,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17878cb0-a8f9-43a4-911c-0f94c2a5e3df",
    "patient_ID": "TCGA.AG.A02G",
    "bcr_drug_barcode": "TCGA-AG-A02G-D37684",
    "bcr_drug_uuid": "A8310B34-29AD-410D-A5DE-FCDD7CBE7AEE",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17878cb0-a8f9-43a4-911c-0f94c2a5e3df",
    "patient_ID": "TCGA.AG.A02G",
    "bcr_drug_barcode": "TCGA-AG-A02G-D37685",
    "bcr_drug_uuid": "E6F1FA31-3AF9-45D0-A70B-38EF81B6A288",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "17878cb0-a8f9-43a4-911c-0f94c2a5e3df",
    "patient_ID": "TCGA.AG.A02G",
    "bcr_drug_barcode": "TCGA-AG-A02G-D37686",
    "bcr_drug_uuid": "2DCEA1E6-7D2F-46E0-9D15-4069C8FFC067",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 851,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1096,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8ad1c98b-5395-477e-87a8-19dff3a59c26",
    "patient_ID": "TCGA.AG.A02N",
    "bcr_drug_barcode": "TCGA-AG-A02N-D37687",
    "bcr_drug_uuid": "EB905BAF-E8D7-417B-AA1A-5FA9303ABF20",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "FOLINIC ACID",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 28,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 89,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0bb786ee-07cf-4853-9b49-ec95cd14e282",
    "patient_ID": "TCGA.AG.A032",
    "bcr_drug_barcode": "TCGA-AG-A032-D37688",
    "bcr_drug_uuid": "E547F9F9-E8C7-444D-9948-84C39401718F",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 458,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f2a8deb2-0e2c-4bbd-8fa1-99b7abb2f3aa",
    "patient_ID": "TCGA.AG.A036",
    "bcr_drug_barcode": "TCGA-AG-A036-D37689",
    "bcr_drug_uuid": "5C971E83-8B85-45AE-86A7-2658BC205B5F",
    "form_completion_date": "2012-12-5",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 215,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "835cbd02-4dbb-4273-9704-4b5d272493d7",
    "patient_ID": "TCGA.AH.6544",
    "bcr_drug_barcode": "TCGA-AH-6544-D58962",
    "bcr_drug_uuid": "A7E20535-8B56-47B9-9317-056575B2B34A",
    "form_completion_date": "2014-4-29",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 229,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "835cbd02-4dbb-4273-9704-4b5d272493d7",
    "patient_ID": "TCGA.AH.6544",
    "bcr_drug_barcode": "TCGA-AH-6544-D58963",
    "bcr_drug_uuid": "E0872852-6AFB-4304-9F95-06C0DAE1CC66",
    "form_completion_date": "2014-4-29",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 365,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "835cbd02-4dbb-4273-9704-4b5d272493d7",
    "patient_ID": "TCGA.AH.6544",
    "bcr_drug_barcode": "TCGA-AH-6544-D58964",
    "bcr_drug_uuid": "26178324-9337-4FDE-9138-4CB722F26575",
    "form_completion_date": "2014-4-29",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 243,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 365,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "835cbd02-4dbb-4273-9704-4b5d272493d7",
    "patient_ID": "TCGA.AH.6544",
    "bcr_drug_barcode": "TCGA-AH-6544-D72541",
    "bcr_drug_uuid": "1ED54217-BFD1-4649-BA20-441ACCFBBF6D",
    "form_completion_date": "2015-7-13",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 229,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "835cbd02-4dbb-4273-9704-4b5d272493d7",
    "patient_ID": "TCGA.AH.6544",
    "bcr_drug_barcode": "TCGA-AH-6544-D72542",
    "bcr_drug_uuid": "135340EA-B051-4018-8B82-1B4FDE8149C5",
    "form_completion_date": "2015-7-13",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 68,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 229,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd0ddc1e-ba3b-4719-a2fa-776f0475dd8a",
    "patient_ID": "TCGA.AH.6643",
    "bcr_drug_barcode": "TCGA-AH-6643-D57835",
    "bcr_drug_uuid": "A3494B7C-E0B1-4449-A8D8-3C4470AF9AB4",
    "form_completion_date": "2014-3-27",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 202,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd0ddc1e-ba3b-4719-a2fa-776f0475dd8a",
    "patient_ID": "TCGA.AH.6643",
    "bcr_drug_barcode": "TCGA-AH-6643-D57836",
    "bcr_drug_uuid": "8010F585-8B53-441B-9465-DED992A7E34E",
    "form_completion_date": "2014-3-27",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 202,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd0ddc1e-ba3b-4719-a2fa-776f0475dd8a",
    "patient_ID": "TCGA.AH.6643",
    "bcr_drug_barcode": "TCGA-AH-6643-D57837",
    "bcr_drug_uuid": "85D44224-0FAD-4FD4-B75C-8AFCAF6CBF8D",
    "form_completion_date": "2014-3-27",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 202,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1e89c189-7c8a-44c9-9b0f-2f625a285003",
    "patient_ID": "TCGA.AH.6903",
    "bcr_drug_barcode": "TCGA-AH-6903-D45595",
    "bcr_drug_uuid": "0136A943-A156-450D-89CE-22B658D58AED",
    "form_completion_date": "2013-7-17",
    "pharmaceutical_therapy_drug_name": "5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1e89c189-7c8a-44c9-9b0f-2f625a285003",
    "patient_ID": "TCGA.AH.6903",
    "bcr_drug_barcode": "TCGA-AH-6903-D45596",
    "bcr_drug_uuid": "3AC71EE5-4B1E-4DBE-856A-2B4841E4EDEE",
    "form_completion_date": "2013-7-17",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1e89c189-7c8a-44c9-9b0f-2f625a285003",
    "patient_ID": "TCGA.AH.6903",
    "bcr_drug_barcode": "TCGA-AH-6903-D45597",
    "bcr_drug_uuid": "A49CFDD2-967B-4FC3-8902-594DAA1A2F3A",
    "form_completion_date": "2013-7-17",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 70,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "COMPLETE RESPONSE"
  },
  {
    "bcr_patient_uuid": "a46be4e1-260c-4ce9-8b0f-1326d90c697f",
    "patient_ID": "TCGA.BM.6198",
    "bcr_drug_barcode": "TCGA-BM-6198-D13221",
    "bcr_drug_uuid": "50c06958-f062-4dd4-8af3-2e20727551da",
    "form_completion_date": "2011-6-21",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 78,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 261,
    "regimen_number": 1,
    "drug_route": "ORAL",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "b26143d3-d458-4d5c-8446-fd2f05707352",
    "patient_ID": "TCGA.CI.6620",
    "bcr_drug_barcode": "TCGA-CI-6620-D69556",
    "bcr_drug_uuid": "1F45E610-2ED5-4BF2-9A0B-213C8802E4ED",
    "form_completion_date": "2015-1-13",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 160,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b26143d3-d458-4d5c-8446-fd2f05707352",
    "patient_ID": "TCGA.CI.6620",
    "bcr_drug_barcode": "TCGA-CI-6620-D69557",
    "bcr_drug_uuid": "9B427929-3285-4A24-8FDD-0ADFCB371A7B",
    "form_completion_date": "2015-1-13",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 160,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "b26143d3-d458-4d5c-8446-fd2f05707352",
    "patient_ID": "TCGA.CI.6620",
    "bcr_drug_barcode": "TCGA-CI-6620-D69558",
    "bcr_drug_uuid": "ED3B3488-DA97-4D97-A0A2-C1E0F5900F16",
    "form_completion_date": "2015-1-13",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 39,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 160,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd6877a8-06b4-4b95-bed2-15c524068f21",
    "patient_ID": "TCGA.CI.6622",
    "bcr_drug_barcode": "TCGA-CI-6622-D69594",
    "bcr_drug_uuid": "456BA3A9-364D-4109-AB4E-6E5E75B906F2",
    "form_completion_date": "2015-1-14",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 97,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd6877a8-06b4-4b95-bed2-15c524068f21",
    "patient_ID": "TCGA.CI.6622",
    "bcr_drug_barcode": "TCGA-CI-6622-D69595",
    "bcr_drug_uuid": "852704E9-6A87-4723-A643-5414DEE6DAEC",
    "form_completion_date": "2015-1-14",
    "pharmaceutical_therapy_drug_name": "LEUOCVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 116,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd6877a8-06b4-4b95-bed2-15c524068f21",
    "patient_ID": "TCGA.CI.6622",
    "bcr_drug_barcode": "TCGA-CI-6622-D69596",
    "bcr_drug_uuid": "8DD9165C-7657-44D3-9DB9-AF09646B5A24",
    "form_completion_date": "2015-1-14",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 116,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "bd6877a8-06b4-4b95-bed2-15c524068f21",
    "patient_ID": "TCGA.CI.6622",
    "bcr_drug_barcode": "TCGA-CI-6622-D69597",
    "bcr_drug_uuid": "7E3E8841-F487-467D-AFFE-BA3623C3803B",
    "form_completion_date": "2015-1-14",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 116,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "a2e47568-eb43-4c89-ad7c-dfbaa2ba7e27",
    "patient_ID": "TCGA.CL.4957",
    "bcr_drug_barcode": "TCGA-CL-4957-D10094",
    "bcr_drug_uuid": "c60e340b-0248-41fe-80fd-cef4fac101f3",
    "form_completion_date": "2011-4-00",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 73,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_dose": 65,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "a2e47568-eb43-4c89-ad7c-dfbaa2ba7e27",
    "patient_ID": "TCGA.CL.4957",
    "bcr_drug_barcode": "TCGA-CL-4957-D10096",
    "bcr_drug_uuid": "d4aea7da-592a-47ce-ae43-a801599416d4",
    "form_completion_date": "2011-4-00",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 73,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_dose": 400,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "a2e47568-eb43-4c89-ad7c-dfbaa2ba7e27",
    "patient_ID": "TCGA.CL.4957",
    "bcr_drug_barcode": "TCGA-CL-4957-D10097",
    "bcr_drug_uuid": "287ad8e2-f73e-4ece-ab30-2fe789f2d532",
    "form_completion_date": "2011-4-00",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN CALCIUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 73,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_dose": 400,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "a2e47568-eb43-4c89-ad7c-dfbaa2ba7e27",
    "patient_ID": "TCGA.CL.4957",
    "bcr_drug_barcode": "TCGA-CL-4957-D10095",
    "bcr_drug_uuid": "001b65f0-aff7-4cb6-bf83-050f9370e6ae",
    "form_completion_date": "2011-4-7",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 73,
    "drug_cycles": 3,
    "drug_units": "MG",
    "drug_dose": 1200,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "644571e9-b8e6-42f3-a2e4-33bad0fac661",
    "patient_ID": "TCGA.DC.4745",
    "bcr_drug_barcode": "TCGA-DC-4745-D16792",
    "bcr_drug_uuid": "3ba36058-d0eb-40b6-b5b6-1a57dc54e5ef",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 29000
  },
  {
    "bcr_patient_uuid": "644571e9-b8e6-42f3-a2e4-33bad0fac661",
    "patient_ID": "TCGA.DC.4745",
    "bcr_drug_barcode": "TCGA-DC-4745-D16799",
    "bcr_drug_uuid": "5935d581-743c-4b5e-892c-f90ab7754666",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "PEGFILGRASTIM",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 122,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 204,
    "drug_cycles": 6,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 6,
    "regimen_number": 1,
    "drug_route": "SUBCUTANEOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 36
  },
  {
    "bcr_patient_uuid": "644571e9-b8e6-42f3-a2e4-33bad0fac661",
    "patient_ID": "TCGA.DC.4745",
    "bcr_drug_barcode": "TCGA-DC-4745-D16789",
    "bcr_drug_uuid": "56e97bd0-ae1f-4321-9da2-1c4fcebd711d",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 9600
  },
  {
    "bcr_patient_uuid": "644571e9-b8e6-42f3-a2e4-33bad0fac661",
    "patient_ID": "TCGA.DC.4745",
    "bcr_drug_barcode": "TCGA-DC-4745-D16795",
    "bcr_drug_uuid": "2e038d05-efc6-45e4-b011-af9a6669eda3",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN CALCIUM",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "drug_cycles": 12,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "OTHER",
    "drug_total_dose": 9600
  },
  {
    "bcr_patient_uuid": "644571e9-b8e6-42f3-a2e4-33bad0fac661",
    "patient_ID": "TCGA.DC.4745",
    "bcr_drug_barcode": "TCGA-DC-4745-D16798",
    "bcr_drug_uuid": "abf58812-4c12-4734-ba99-80b3e107572f",
    "form_completion_date": "2011-9-26",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 62,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 132,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 170,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1020
  },
  {
    "bcr_patient_uuid": "33e91116-8844-4861-843d-784c70b4a6fc",
    "patient_ID": "TCGA.DC.6154",
    "bcr_drug_barcode": "TCGA-DC-6154-D17886",
    "bcr_drug_uuid": "ae7103e5-b431-4be0-b041-09485384352a",
    "form_completion_date": "2011-10-27",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 91,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "drug_cycles": 12,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "33e91116-8844-4861-843d-784c70b4a6fc",
    "patient_ID": "TCGA.DC.6154",
    "bcr_drug_barcode": "TCGA-DC-6154-D17883",
    "bcr_drug_uuid": "1535646c-5346-457e-8157-8083e674308f",
    "form_completion_date": "2011-10-27",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 91,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "drug_cycles": 12,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "33e91116-8844-4861-843d-784c70b4a6fc",
    "patient_ID": "TCGA.DC.6154",
    "bcr_drug_barcode": "TCGA-DC-6154-D17888",
    "bcr_drug_uuid": "31ab0762-6f93-45f0-910b-0cc012bfbde4",
    "form_completion_date": "2011-10-27",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 91,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "drug_cycles": 12,
    "pharma_type_other": "ANCILLARY",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "33e91116-8844-4861-843d-784c70b4a6fc",
    "patient_ID": "TCGA.DC.6154",
    "bcr_drug_barcode": "TCGA-DC-6154-D17889",
    "bcr_drug_uuid": "ca705d57-a0eb-4310-8628-44af85e60bb9",
    "form_completion_date": "2011-10-27",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 91,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 242,
    "drug_cycles": 12,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "eb75ca70-e60f-453f-820c-485390abad88",
    "patient_ID": "TCGA.DC.6155",
    "bcr_drug_barcode": "TCGA-DC-6155-D15163",
    "bcr_drug_uuid": "c6d39c6c-9b36-4771-9d2b-f7fd8791e5f4",
    "form_completion_date": "2011-8-12",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 57,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 71,
    "drug_cycles": 2,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 130,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 260
  },
  {
    "bcr_patient_uuid": "eb75ca70-e60f-453f-820c-485390abad88",
    "patient_ID": "TCGA.DC.6155",
    "bcr_drug_barcode": "TCGA-DC-6155-D15164",
    "bcr_drug_uuid": "0b815912-6451-40de-8bdf-676366ba19f1",
    "form_completion_date": "2011-8-12",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 57,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "drug_cycles": 11,
    "pharma_type_other": "ANCILLARY AGENT",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 5970
  },
  {
    "bcr_patient_uuid": "eb75ca70-e60f-453f-820c-485390abad88",
    "patient_ID": "TCGA.DC.6155",
    "bcr_drug_barcode": "TCGA-DC-6155-D15166",
    "bcr_drug_uuid": "f7f4fe18-913d-4ce0-82a3-d4dc4d4b8759",
    "form_completion_date": "2011-8-12",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 57,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 7600
  },
  {
    "bcr_patient_uuid": "eb75ca70-e60f-453f-820c-485390abad88",
    "patient_ID": "TCGA.DC.6155",
    "bcr_drug_barcode": "TCGA-DC-6155-D15168",
    "bcr_drug_uuid": "2280d088-6312-4936-90a6-1076aecf0b11",
    "form_completion_date": "2011-8-12",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 57,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 1900,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 22800
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D15196",
    "bcr_drug_uuid": "60a99194-92a3-4737-a849-330f061aa523",
    "form_completion_date": "2011-8-15",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 87,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 170,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 1830
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D15198",
    "bcr_drug_uuid": "c3baaf92-b499-4f7a-9431-70b545c0e8d3",
    "form_completion_date": "2011-8-15",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 334,
    "drug_cycles": 17,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 13600
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D15197",
    "bcr_drug_uuid": "f501c115-db91-4cde-acb1-35d17cf23bed",
    "form_completion_date": "2011-8-15",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 334,
    "drug_cycles": 17,
    "pharma_type_other": "ANCILLARY AGENT",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 210,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 3570
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D15199",
    "bcr_drug_uuid": "609c5cb0-e725-45d6-991d-6064fdca9e45",
    "form_completion_date": "2011-8-15",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 92,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 334,
    "drug_cycles": 17,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 2400,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 35500
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D21979",
    "bcr_drug_uuid": "d409689c-b0f7-406a-bb0d-f9f1dc4b774f",
    "form_completion_date": "2012-2-22",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN HCL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 365,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 380,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 2800
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D21980",
    "bcr_drug_uuid": "54129ecf-0125-45a8-8506-eb8248500ae8",
    "form_completion_date": "2012-2-22",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 395,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 6,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 480,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 2880
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D29374",
    "bcr_drug_uuid": "f4c74905-0f74-43ef-993d-bf84e70f61c1",
    "form_completion_date": "2012-3-16",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 365,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 320,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 2368
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D29373",
    "bcr_drug_uuid": "7924ad55-eb1c-47f3-a2b5-aefe07edff8d",
    "form_completion_date": "2012-3-16",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 365,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 5920
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D29375",
    "bcr_drug_uuid": "e8158296-a375-4c50-a27d-a7021b3a07d3",
    "form_completion_date": "2012-3-16",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 365,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 100,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PALLIATIVE",
    "drug_total_dose": 740
  },
  {
    "bcr_patient_uuid": "261925e3-96e4-440c-8e95-c003d44ab2f2",
    "patient_ID": "TCGA.DC.6156",
    "bcr_drug_barcode": "TCGA-DC-6156-D44758",
    "bcr_drug_uuid": "45C103CA-FAFA-4BE8-96BB-786E15D2D8CA",
    "form_completion_date": "2013-6-26",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 395,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 761,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3e97286f-8aa8-4b6a-b339-d7a8e30f60c2",
    "patient_ID": "TCGA.DC.6681",
    "bcr_drug_barcode": "TCGA-DC-6681-D17001",
    "bcr_drug_uuid": "0389e5fe-ae72-4684-8857-a1786571f0fc",
    "form_completion_date": "2011-9-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 136,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 600,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 3920
  },
  {
    "bcr_patient_uuid": "3e97286f-8aa8-4b6a-b339-d7a8e30f60c2",
    "patient_ID": "TCGA.DC.6681",
    "bcr_drug_barcode": "TCGA-DC-6681-D17003",
    "bcr_drug_uuid": "70773b35-24f4-40be-8d08-4e29f9b40993",
    "form_completion_date": "2011-9-29",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 136,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 1900,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 15200
  },
  {
    "bcr_patient_uuid": "3e97286f-8aa8-4b6a-b339-d7a8e30f60c2",
    "patient_ID": "TCGA.DC.6681",
    "bcr_drug_barcode": "TCGA-DC-6681-D17004",
    "bcr_drug_uuid": "db7f6761-c134-48ba-b2f3-df57a979b4b1",
    "form_completion_date": "2011-9-29",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN CALCIUM",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 136,
    "drug_cycles": 8,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 160,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1280
  },
  {
    "bcr_patient_uuid": "3e97286f-8aa8-4b6a-b339-d7a8e30f60c2",
    "patient_ID": "TCGA.DC.6681",
    "bcr_drug_barcode": "TCGA-DC-6681-D17005",
    "bcr_drug_uuid": "f49b8f63-3f14-47e6-ac92-e3fe637e5299",
    "form_completion_date": "2011-9-29",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 136,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 110,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 850
  },
  {
    "bcr_patient_uuid": "16a9e1c5-85c2-4930-a16c-af59114bac9a",
    "patient_ID": "TCGA.DC.6683",
    "bcr_drug_barcode": "TCGA-DC-6683-D16998",
    "bcr_drug_uuid": "102d8593-ffff-4a1e-8f0d-0d8e1dac97af",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 214,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 170,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1980
  },
  {
    "bcr_patient_uuid": "16a9e1c5-85c2-4930-a16c-af59114bac9a",
    "patient_ID": "TCGA.DC.6683",
    "bcr_drug_barcode": "TCGA-DC-6683-D16997",
    "bcr_drug_uuid": "7b26e472-0f10-4ca1-9bb1-4dbd2a4852e9",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 214,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 2400,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 28800
  },
  {
    "bcr_patient_uuid": "16a9e1c5-85c2-4930-a16c-af59114bac9a",
    "patient_ID": "TCGA.DC.6683",
    "bcr_drug_barcode": "TCGA-DC-6683-D16996",
    "bcr_drug_uuid": "c35d6f62-4fe4-460c-9ca1-eef4461e775d",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 214,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 9600
  },
  {
    "bcr_patient_uuid": "16a9e1c5-85c2-4930-a16c-af59114bac9a",
    "patient_ID": "TCGA.DC.6683",
    "bcr_drug_barcode": "TCGA-DC-6683-D17000",
    "bcr_drug_uuid": "d212da89-e3a1-4588-ab55-5f0513443f06",
    "form_completion_date": "2012-4-18",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN CALCIUM",
    "pharmaceutical_therapy_type": "OTHER, SPECIFY IN NOTES",
    "days_to_drug_start": 50,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 214,
    "drug_cycles": 12,
    "pharma_type_other": "ANCILLARY",
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 800,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 9600
  },
  {
    "bcr_patient_uuid": "9df9af6b-00b0-47af-aac7-b52dac399ba5",
    "patient_ID": "TCGA.DY.A0XA",
    "bcr_drug_barcode": "TCGA-DY-A0XA-D30448",
    "bcr_drug_uuid": "3A895248-930E-46DE-99A6-2D6B7732C640",
    "form_completion_date": "2012-4-10",
    "pharmaceutical_therapy_drug_name": "MAYO 425-20",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 47,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 239,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "205f30ff-fb10-44a8-a1c6-c538de100db5",
    "patient_ID": "TCGA.DY.A1DC",
    "bcr_drug_barcode": "TCGA-DY-A1DC-D30402",
    "bcr_drug_uuid": "1DD51FDD-A9D3-4ECD-B3DF-F74DABB7F28D",
    "form_completion_date": "2012-4-10",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE -XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 771,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 828,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5555fbdd-962f-4d79-b36c-ae3c3cc4aff4",
    "patient_ID": "TCGA.DY.A1DE",
    "bcr_drug_barcode": "TCGA-DY-A1DE-D30446",
    "bcr_drug_uuid": "D369621F-ABAD-4DC9-B8ED-BAC84CF0BFB5",
    "form_completion_date": "2012-4-10",
    "pharmaceutical_therapy_drug_name": "MAYO 425-20",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 46,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 78,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5555fbdd-962f-4d79-b36c-ae3c3cc4aff4",
    "patient_ID": "TCGA.DY.A1DE",
    "bcr_drug_barcode": "TCGA-DY-A1DE-D30447",
    "bcr_drug_uuid": "2B357047-E9A9-473A-9D6C-0DFD7D0DE8C8",
    "form_completion_date": "2012-4-10",
    "pharmaceutical_therapy_drug_name": "MAYO 425-20",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 291,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 379,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "d8bfcc67-f5c3-42cd-9fc4-bd483f896da1",
    "patient_ID": "TCGA.EI.6508",
    "bcr_drug_barcode": "TCGA-EI-6508-D28936",
    "bcr_drug_uuid": "a4922b17-c151-4bac-bd9d-a607e43949e8",
    "form_completion_date": "2012-3-2",
    "pharmaceutical_therapy_drug_name": "OXALIPLATINUM + 5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 76,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 258,
    "drug_cycles": 12,
    "drug_units": "MG/M2/DAY",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "652e503a-1be8-445b-96d6-ff114f911e76",
    "patient_ID": "TCGA.EI.6509",
    "bcr_drug_barcode": "TCGA-EI-6509-D28629",
    "bcr_drug_uuid": "04e8bf95-c20c-4276-a4ca-0acf83597ea1",
    "form_completion_date": "2012-2-27",
    "pharmaceutical_therapy_drug_name": "FOLFOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 395,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "d004a083-6dc6-4db6-96d0-88a8ca3b1b93",
    "patient_ID": "TCGA.EI.6511",
    "bcr_drug_barcode": "TCGA-EI-6511-D28932",
    "bcr_drug_uuid": "CA39B724-0291-4EB0-87A1-D85C280C3964",
    "form_completion_date": "2012-3-2",
    "pharmaceutical_therapy_drug_name": "OXALIPLATINUM+5-FU",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 161,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 182,
    "drug_cycles": 3,
    "drug_units": "MG/M2/DAY",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "25b43e40-e1f9-42a0-8052-5138f381eed9",
    "patient_ID": "TCGA.EI.6512",
    "bcr_drug_barcode": "TCGA-EI-6512-D28635",
    "bcr_drug_uuid": "b21dc457-7653-4411-931f-6d024c1c33c1",
    "form_completion_date": "2012-2-27",
    "pharmaceutical_therapy_drug_name": "FOLFOX",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 20,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "40974ab3-e532-4d6e-9c98-ee640f3976d6",
    "patient_ID": "TCGA.EI.6514",
    "bcr_drug_barcode": "TCGA-EI-6514-D28631",
    "bcr_drug_uuid": "139796C1-BFC0-4707-9CF2-52A9843422B6",
    "form_completion_date": "2012-2-27",
    "pharmaceutical_therapy_drug_name": "5-FU + LEULOV",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 27,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 88,
    "drug_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "3aecf83e-c614-4ffa-8c82-1b5dadf6509e",
    "patient_ID": "TCGA.EI.6881",
    "bcr_drug_barcode": "TCGA-EI-6881-D29850",
    "bcr_drug_uuid": "b66c7bf1-c626-40ca-b707-a3848b2bdd0b",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "5 FLUOROURACIL+LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 250,
    "drug_cycles": 6,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "468c2ecb-a21f-49a7-91f3-63d3ef266cf8",
    "patient_ID": "TCGA.EI.6883",
    "bcr_drug_barcode": "TCGA-EI-6883-D29852",
    "bcr_drug_uuid": "f1e06e96-ffc3-4cf9-962b-2e718c64a40e",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "5FLUOROURACIL+LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 55,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 111,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "b2b125c7-8993-4424-b390-048ccccc9d08",
    "patient_ID": "TCGA.EI.6884",
    "bcr_drug_barcode": "TCGA-EI-6884-D29853",
    "bcr_drug_uuid": "36a71370-2d4f-45ac-8144-14a8731a5ce6",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "5 FLUOROURACILUM+LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 52,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG/KG",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "3165bf70-df19-4043-bcfc-9ae92197ef72",
    "patient_ID": "TCGA.EI.6885",
    "bcr_drug_barcode": "TCGA-EI-6885-D29907",
    "bcr_drug_uuid": "b055a1f4-d417-4577-9543-dac2a5baa90d",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "OXALIPLATINUM+5 FLUOROURACILUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 69,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 308,
    "drug_cycles": 12,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "0cb21fb0-520f-4105-99ec-697a335115b5",
    "patient_ID": "TCGA.EI.6917",
    "bcr_drug_barcode": "TCGA-EI-6917-D29855",
    "bcr_drug_uuid": "4e8e5e86-a3d0-4b3d-b936-bc4046da5b55",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "5FLUOROURACIL+OXACIPLATINA+L-FOLINIAN DISCIDO",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 100,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 145,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "2b1783da-9ede-4590-b96a-6b0eabc8777f",
    "patient_ID": "TCGA.EI.7002",
    "bcr_drug_barcode": "TCGA-EI-7002-D29904",
    "bcr_drug_uuid": "cfb19b7d-cb95-4630-a70b-ccae74ce829b",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN+5-FLUOROURACILIM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 67,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 224,
    "drug_cycles": 12,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "b2db7f47-540f-4bd3-81bb-d686b0225201",
    "patient_ID": "TCGA.EI.7004",
    "bcr_drug_barcode": "TCGA-EI-7004-D29858",
    "bcr_drug_uuid": "f1a23525-1b5a-4f36-93f3-2c78da97de62",
    "form_completion_date": "2012-3-30",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 41,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 188,
    "drug_cycles": 7,
    "drug_units": "MG/M2",
    "drug_tota_dose_units": "MG",
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D29834",
    "bcr_drug_uuid": "857CE230-D7C1-4EC3-A8E3-327337A6A5CD",
    "form_completion_date": "2012-3-29",
    "pharmaceutical_therapy_drug_name": "CAPECITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 226,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 350,
    "drug_cycles": 6,
    "drug_units": "G/DAY",
    "drug_tota_dose_units": "G/DAY",
    "drug_dose": 4,
    "drug_route": "ORAL",
    "therapy_regimen": "RECURRENCE",
    "drug_total_dose": 336
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D53525",
    "bcr_drug_uuid": "2B9D27E5-E361-4657-8DA6-21B9D8454DFD",
    "form_completion_date": "2013-12-12",
    "pharmaceutical_therapy_drug_name": "MITOMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 770,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 813,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D53527",
    "bcr_drug_uuid": "2F82A9D7-83B1-4A8F-9EC8-D81BDCBF24B4",
    "form_completion_date": "2013-12-12",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 847,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 952,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D53530",
    "bcr_drug_uuid": "08406C00-17CA-42E1-BB5F-919DD9BE7FD8",
    "form_completion_date": "2013-12-12",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 847,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 952,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D53531",
    "bcr_drug_uuid": "E3940B66-3CF4-4484-A360-2A1E70F345EB",
    "form_completion_date": "2013-12-12",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 847,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 952,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D65905",
    "bcr_drug_uuid": "AF8F3EF6-1533-41EA-9E07-49767EF773FB",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "IRINOTECAN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1065,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1157,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D65907",
    "bcr_drug_uuid": "752ADA80-5EDC-4F56-AEF4-F64C81591C01",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 1065,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1157,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D65909",
    "bcr_drug_uuid": "EB1AB997-77FB-4F19-A8CE-2B4F475F4548",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1065,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1157,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D65922",
    "bcr_drug_uuid": "BFAF1A47-D8B9-4307-AB33-423277F0B8F8",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1065,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D65923",
    "bcr_drug_uuid": "55F67205-87D7-49DF-85D4-77DBA50B9A0A",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1255,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "85947797-54b8-44fb-910b-5cd689542994",
    "patient_ID": "TCGA.F5.6571",
    "bcr_drug_barcode": "TCGA-F5-6571-D65924",
    "bcr_drug_uuid": "82FA8F68-90F5-42E8-8ABF-5A8C488D0F1E",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1255,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f1ce4b5f-55d0-4989-a5f3-6b6e591538b2",
    "patient_ID": "TCGA.F5.6702",
    "bcr_drug_barcode": "TCGA-F5-6702-D46350",
    "bcr_drug_uuid": "AE38DEA3-6C5A-423C-B49F-86D4DCE40ED9",
    "form_completion_date": "2013-8-6",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 370,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 641,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f1ce4b5f-55d0-4989-a5f3-6b6e591538b2",
    "patient_ID": "TCGA.F5.6702",
    "bcr_drug_barcode": "TCGA-F5-6702-D46351",
    "bcr_drug_uuid": "4A439625-FA84-45EC-817B-67C23AFE1E37",
    "form_completion_date": "2013-8-6",
    "pharmaceutical_therapy_drug_name": "POLYPLATILLEN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 370,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 641,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "f1ce4b5f-55d0-4989-a5f3-6b6e591538b2",
    "patient_ID": "TCGA.F5.6702",
    "bcr_drug_barcode": "TCGA-F5-6702-D46352",
    "bcr_drug_uuid": "A119CEAA-1B12-4770-B8B6-D4D1D7A38F0F",
    "form_completion_date": "2013-8-6",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 340,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 551,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72e640f2-869f-4aef-8ebe-b127f3e7048a",
    "patient_ID": "TCGA.F5.6863",
    "bcr_drug_barcode": "TCGA-F5-6863-D35412",
    "bcr_drug_uuid": "52352390-D906-4CD9-A1EF-85A68856259C",
    "form_completion_date": "2012-9-26",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 196,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 251,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72e640f2-869f-4aef-8ebe-b127f3e7048a",
    "patient_ID": "TCGA.F5.6863",
    "bcr_drug_barcode": "TCGA-F5-6863-D35413",
    "bcr_drug_uuid": "C49E0FEE-4847-4946-83B7-457EE6C96D86",
    "form_completion_date": "2012-9-26",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 196,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 251,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72e640f2-869f-4aef-8ebe-b127f3e7048a",
    "patient_ID": "TCGA.F5.6863",
    "bcr_drug_barcode": "TCGA-F5-6863-D35414",
    "bcr_drug_uuid": "A8C20AB5-CB1C-4F37-B128-2926781CD0FF",
    "form_completion_date": "2012-9-26",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 196,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 251,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "72e640f2-869f-4aef-8ebe-b127f3e7048a",
    "patient_ID": "TCGA.F5.6863",
    "bcr_drug_barcode": "TCGA-F5-6863-D35415",
    "bcr_drug_uuid": "DDBA0B34-8873-49AE-865D-C33764098442",
    "form_completion_date": "2012-9-26",
    "pharmaceutical_therapy_drug_name": "XELODA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 261,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 289,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3546a93b-b279-4615-9d5f-5baa787e487e",
    "patient_ID": "TCGA.F5.6864",
    "bcr_drug_barcode": "TCGA-F5-6864-D33874",
    "bcr_drug_uuid": "A7C58EE8-6D8E-465B-879A-863167346D8A",
    "form_completion_date": "2012-7-23",
    "pharmaceutical_therapy_drug_name": "5-FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 17,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 191,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3546a93b-b279-4615-9d5f-5baa787e487e",
    "patient_ID": "TCGA.F5.6864",
    "bcr_drug_barcode": "TCGA-F5-6864-D33875",
    "bcr_drug_uuid": "591BBBE2-4B58-48F4-B353-932C79B86C0F",
    "form_completion_date": "2012-7-23",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 17,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 191,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ff427104-0727-483c-8513-243dec80db9d",
    "patient_ID": "TCGA.G5.6233",
    "bcr_drug_barcode": "TCGA-G5-6233-D21974",
    "bcr_drug_uuid": "5646f05f-fd36-42e5-8ff3-7e36ff7ad118",
    "form_completion_date": "2012-2-6",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 270,
    "drug_cycles": 9,
    "regimen_number": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "ff427104-0727-483c-8513-243dec80db9d",
    "patient_ID": "TCGA.G5.6233",
    "bcr_drug_barcode": "TCGA-G5-6233-D21976",
    "bcr_drug_uuid": "de57c88f-e829-4be0-8365-eee4b531dd1d",
    "form_completion_date": "2012-2-6",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 270,
    "drug_cycles": 9,
    "regimen_number": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "ff427104-0727-483c-8513-243dec80db9d",
    "patient_ID": "TCGA.G5.6233",
    "bcr_drug_barcode": "TCGA-G5-6233-D21971",
    "bcr_drug_uuid": "8151e8a5-d1e3-4f9f-b00c-c87ca2e13f6b",
    "form_completion_date": "2012-2-6",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 270,
    "drug_cycles": 9,
    "regimen_number": 1,
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "c2ea7b58-cabd-407e-98ce-6cbf9e4d93e1",
    "patient_ID": "TCGA.G5.6235",
    "bcr_drug_barcode": "TCGA-G5-6235-D21955",
    "bcr_drug_uuid": "05fe541d-4408-48c0-88e2-865b333fb9e5",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 33,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 187,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 720,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 8848
  },
  {
    "bcr_patient_uuid": "c2ea7b58-cabd-407e-98ce-6cbf9e4d93e1",
    "patient_ID": "TCGA.G5.6235",
    "bcr_drug_barcode": "TCGA-G5-6235-D21956",
    "bcr_drug_uuid": "b0ca40c0-6174-4371-bf39-12d2ff45d079",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 33,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 187,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 150,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1880
  },
  {
    "bcr_patient_uuid": "c2ea7b58-cabd-407e-98ce-6cbf9e4d93e1",
    "patient_ID": "TCGA.G5.6235",
    "bcr_drug_barcode": "TCGA-G5-6235-D21953",
    "bcr_drug_uuid": "b59a484b-cd0a-4482-ab1d-4310539df12e",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 89,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 187,
    "drug_cycles": 8,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 740,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 5968
  },
  {
    "bcr_patient_uuid": "0a2cb2f9-972c-450c-8b7a-115a4cb93658",
    "patient_ID": "TCGA.G5.6641",
    "bcr_drug_barcode": "TCGA-G5-6641-D21865",
    "bcr_drug_uuid": "d81354b9-0c34-4fcc-8b3f-e3f107f69534",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "OXALIPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 100,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 212,
    "drug_cycles": 9,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 210,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 1862
  },
  {
    "bcr_patient_uuid": "0a2cb2f9-972c-450c-8b7a-115a4cb93658",
    "patient_ID": "TCGA.G5.6641",
    "bcr_drug_barcode": "TCGA-G5-6641-D21867",
    "bcr_drug_uuid": "5bf0d06d-1ace-46e0-a4ca-0994b79721e7",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "FLUOROURACIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 100,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 254,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 980,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 11632
  },
  {
    "bcr_patient_uuid": "0a2cb2f9-972c-450c-8b7a-115a4cb93658",
    "patient_ID": "TCGA.G5.6641",
    "bcr_drug_barcode": "TCGA-G5-6641-D21868",
    "bcr_drug_uuid": "9a002138-e55e-40ed-bc8d-9878e0bdcd74",
    "form_completion_date": "2012-2-7",
    "pharmaceutical_therapy_drug_name": "LEUCOVORIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 100,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 254,
    "drug_cycles": 12,
    "drug_units": "MG",
    "drug_tota_dose_units": "MG",
    "drug_dose": 980,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 11632
  }
]
